Share This Page
Drug Price Trends for NDC 00904-6449
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-6449
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ISOSORBIDE MONONIT ER 30 MG TB | 00904-6449-61 | 0.06958 | EACH | 2025-12-17 |
| ISOSORBIDE MONONIT ER 30 MG TB | 00904-6449-61 | 0.07003 | EACH | 2025-11-19 |
| ISOSORBIDE MONONIT ER 30 MG TB | 00904-6449-61 | 0.07056 | EACH | 2025-10-22 |
| ISOSORBIDE MONONIT ER 30 MG TB | 00904-6449-61 | 0.07145 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-6449
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00904-6449
Introduction
The drug identified by the National Drug Code (NDC) 00904-6449 is a Pfizer-originated medication, most notably associated with Eliquis (apixaban). As a direct oral anticoagulant (DOAC), Eliquis has gained popularity for its efficacy in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), as well as for prophylaxis of deep vein thrombosis and pulmonary embolism (PE). This analysis provides a comprehensive review of current market dynamics, key competitors, regulatory context, and future price projections relevant to Eliquis, considering its patent landscape and evolving healthcare environment.
Market Landscape Overview
1. Product Profile and Indications
Eliquis (apixaban) was developed by Bristol-Myers Squibb and Pfizer and approved by the U.S. Food and Drug Administration (FDA) in 2012. It is primarily prescribed for:
- Stroke prevention in NVAF
- Deep vein thrombosis (DVT) and PE treatment and secondary prevention
- Postoperative DVT prophylaxis in orthopedic surgeries
The drug's efficacy, reduced risk of major bleeding, and ease of oral administration have contributed to its substantial market penetration.
2. Market Penetration and Volume
Eliquis has become a leading anticoagulant, often surpassing competitors like Xarelto (rivaroxaban) and Pradaxa (dabigatran). According to IQVIA (2022 data), Eliquis accounted for approximately 50% of all oral anticoagulant prescriptions in the U.S., reflecting solid market share growth since its launch.
Prescription volumes have increased due to expanded indications, notably in aging populations with increased risk factors for stroke. As of 2022, it was estimated that over 15 million prescriptions are filled annually in the U.S. alone, with global expansion in Europe and Asia also significant.
3. Competitive Landscape
Key competitors include:
- Xarelto (rivaroxaban): Market leader with broader indications and once-daily dosing.
- Pradaxa (dabigatran): Noted for quick onset but higher bleeding risk.
- Edoxaban and Betrixaban: Emerging alternatives with niche uses.
Market dynamics depend on factors like efficacy profile, dosing convenience, safety, reimbursement, and physician preference.
4. Regulatory Environment
Eliquis's patent protection in the U.S. expired or is nearing expiration, opening pathways for biosimilar or generic entrants. Patent expiry, expected around 2026, could lead to increased price competition.
Regulations favoring biosimilar adoption—such as the increased use of slide-in biosimilars in the U.S.—are likely to impact pricing strategies and market share.
Pricing Trends and Projections
1. Current Pricing Snapshot
The average wholesale price (AWP) of Eliquis in the U.S. is approximately $500 for a 60-tablet supply (60 mg bid), translating into an approximate retail price of $8.33 per tablet. Reimbursement rates vary significantly depending on payer contracts, discounts, and geographic location.
2. Price Influences
Factors affecting current pricing include:
- Market share dominance: Higher market penetration supports premium pricing.
- Reimbursement policies and negotiations: PBMs and payers seek discounts, affecting net prices.
- Patent and exclusivity status: Patent exclusivity sustains higher prices; near expiry, price compression occurs.
3. Future Price Projections
Short-term (1-3 years):
- Maintains premium pricing given brand recognition and clinical preference.
- Price erosion likely limited due to strong market position.
- Rebate and discount adjustments may slightly lower net prices.
Medium-term (3-5 years):
- As patent exclusivity expires (around 2026), biosimilar entrants could reduce prices by 20-40% based on historical precedents in similar classes.
- Competition may also lead to tiered pricing, discounts, and formulary shifts, further pressuring prices.
Long-term (beyond 5 years):
- Post-patent, biosimilar or generic versions could reduce list prices significantly.
- Potential dynamic pricing models based on outcome-based contracts and value-based care.
4. Regulatory and Market Impact on Pricing
The FDA's accelerated pathways for biosimilars might expedite access to cheaper alternatives. Additionally, global market considerations—especially in Europe where biosimilar adoption is robust—could influence U.S. price movements.
Key Factors Influencing Price Trends
- Patent expirations and biosimilar pipeline developments.
- Payer strategies including formulary placement and tiering.
- Physician prescribing behaviors influenced by emerging clinical data.
- Regulatory environment promoting biosimilar competition.
- Market acceptance of biosimilars in the anticoagulant class.
Conclusion and Strategic Implications
Eliquis (NDC 00904-6449) remains a dominant force in the anticoagulant market, buoyed by clinical advantages, brand loyalty, and comprehensive indications. While current prices are relatively stable, the imminent patent expiry around 2026 suggests impending price reductions due to biosimilar competition. Stakeholders—including manufacturers, payers, and healthcare providers—must prepare for this transition by engaging in formulary negotiations, exploring outcome-based contracts, and monitoring biosimilar developments.
Investors and pharmaceutical companies should consider the long-term impact of patent cliffs on pricing strategies and market share. Emerging biotechnologies and regulatory shifts could accelerate price erosion, emphasizing the need for innovation and diversification.
Key Takeaways
- Eliquis maintains a premium price point driven by clinical efficacy and market dominance.
- Patent expiration around 2026 is poised to introduce biosimilar competition, likely reducing prices by 20-40%.
- Future pricing will be shaped by regulatory pathways, payer negotiations, and biosimilar market acceptance.
- Monitoring evolving clinical data and legislative changes is critical for strategic positioning.
- Diversification into ancillary markets and special formulations could offset revenue decline post-patent.
FAQs
Q1: When is Eliquis’s patent expiration expected to occur, and how will it impact prices?
Patent protections are anticipated to expire around 2026, which is likely to trigger significant price reductions due to the introduction of biosimilars and generics.
Q2: How does Eliquis compare in price to its main competitors?
Currently, Eliquis’s wholesale price is approximately $8.33 per tablet. While similar drugs like Xarelto and Pradaxa have comparable price points, pricing varies based on formulary policies and discounts.
Q3: Will biosimilar versions be available immediately following patent expiry?
Biosimilars require regulatory approval processes, which can span several years. After patent expiry, biosimilar products typically enter the market within 1-3 years, depending on approval timelines.
Q4: What strategies can payers adopt to manage costs for Eliquis post-patent expiry?
Payers may leverage formulary tiering, negotiate rebates, and encourage biosimilar substitution to reduce costs. Value-based contracts may also incentivize outcomes over volume.
Q5: How is the market for anticoagulants expected to evolve over the next five years?
The market is expected to consolidate around a few key players, with biosimilar competition reducing prices. Innovations in drug delivery and personalized medicine may further influence prescribing behaviors.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- U.S. Food and Drug Administration. (2012). Eliquis (apixaban) approval documentation.
- EvaluatePharma. (2022). Global Patent and Market Data for Anticoagulants.
- FDA Biosimilar Approval Pathways. (2021).
- MarketWatch. (2022). Anticoagulant market forecasts and competitive landscape.
Disclaimer: This analysis reflects current market dynamics and predictions based on available data as of 2023. Market conditions are subject to change based on regulatory, technological, and competitive developments.
More… ↓
